BAB VII KESIMPULAN DAN SARAN
7.2 Saran
1. Untuk peneliti, dapat dijadikan informasi berupa fakta-fakta yang berkenaan dengan angka kejadian Hipertensi pada penderita hiperurisemia di Rumah Sakit Universitas Hasanuddin Makassar periode Juni 2016-Juni 2017 sehingga dapat dilakukan penelitian lebih lanjut mengenai hubungan hiperurisemia dengan hipertensi ataupun meneliti dalam cakupan sampel yang lebih luas.
2. Untuk tenaga kesehatan, dapat dijadikan masukan agar dapat meningkatkan program pelayanan kesehatan dalam langkah pencegahan dan perawatan. Sehingga meningkatkan kualitas kesehatan masyarakat, serta sebagai bahan masukan bagi instansi kesehatan untuk digunakan sebagai dasar pertimbangan dalam mengambil dan memutuskan kebijakan-kebijakan kesehatan.
3. Untuk masyarakat, dapat dijadikan informasi mengenai pentingnya mengontrol kandungan purin dalam diet bagi meminimalkan resiko timbulnya hiperurisemia yang dalam penelitian ini diduga dapat menyebabkan hipertensi dan pelbagai komoriditas.
65
DAFTAR PUSTAKA
Anwar T. 2008. Faktor resiko penyakit jantung koroner. Medan: Fakultas Kedokteran Universitas Sumatera Utara
Bratawidjaja KG. 2002. Imunologi Dasar. Jakarta: FKUI, pp: 44-53.
Berry CE and JM Hare. 2004. Xanthine Oxidoreductase and Cardiovascular Disease: Molecular Mechanism and Pathophysiological Implications. Am J Physiol, pp: 589-606.
Budiyanto, Cakro. Hubungan Hipertensi dan Diabetes Mellitus terhadap Gagal Ginjal Kronik. Kedokteran Islam; 2009
Darmawan J, Valkenburg HA, Muirden KD, Wigley RD. The epidemiology of gout and hyperuricaemia in a rural population of Java. J Rheumatol 1992, 19, pp1595-9
Departemen Kesehatan. 2013. Laporan Riset Kesehatan Dasar (Riskesdes) 2013 Bidang Biomedis. Jakarta: Badan Litbangkes, Depkes RI, 2013
Derhaschnig U, et al J Hum Hypertens. 2014 Jul;28(7):427-31.
Doi:10.1038/jhh.2013.132. Epub 2014 Jan 16
Dinas Kesehatan Prov. Sulawesi Selatan, 2014. Profil Kesehatan Provinsi Sulawesi Selatan, Makassar: Sistem Informasi Kesehatan Dinkes Provinsi Sulsel
Dincer HE, Dincer AP, Levinson DJ. 2002. Asymptomatic Hyperuricemia: To Treat or Not To Treat. Cleveland Clinic Journal of Medicine, pp: 594-606 Eckel, R.H., 2012. The Metabolic Syndrome. Dalam: Longo, D.L. dkk Harrisons
Principles of Internal Medicine. Vol. 2, 18th edition. New York: McGraw Hill
Edward NL. Gout: Clinical features. In Klippel JH, Stone JH, Crofford LJ, White PH, Editors. 3thed. New York:Springer; 2008.p.241-9
Feig DI, Kang DH, Johnson RJ. 2008. Uric acid and Cardiovascular Risk. N Eng J Med, pp: 1811-21
Firestein GS, Budd RC, Harris RD, Rudy S, Sergen JS, 2009. (eds) Kelley’s textbook of Rheumatology. 8th edition, Philadelphia: W.B Saunders
Hansen, T.R.P 2007. Hubungan konsumsi purin dengan hiperurisemia pada suku Bali di daerah pariwisata pendesaan. Jurnal Penyakit Dalam, Vol. 8 No.1
66
Hediger MA, Johnson RJ, Miyazaki H, Endou H. 2005. Molecular Physiology of Urate Transport. Am J Physiol, pp: 125-33.
Heinig M and RJ Johnson. 2006. Role of Uric Acid in Hypertension, Renal Disease, and Metabolic Syndrome. Cleveland Clinic Journal of Medicine, pp: 1059-64.
Joesoef AH dan Budhi Setianto. 2003. Hipertensi Sekunder. In: Rilantono dkk (ed). Buku Ajar Kardiologi. Jakarta: FKUI
Johnson RJ, Kang DH, Feig DI, Kivlighn S, Kanelis J, Watanabe S, Tuttle KR, Mazzali M. 2003. Is There a Pathogenic Rule of Uric Acid in Hypertension, Cardiovascular and Renal Disease? Hypertension Journal, pp: 1183-90.
Kumar V, Abbas AK, Fausto N. Hypertensive Vascular Disease. Dalam: Robn and Cotran Pathologic Basis of Disease, 7th edition. Philadelphia: Elsevier Saunders, 2005.p 528-529
Kotchen, T.A., 2010. Obesity-related Hypertension. American Journal of Hypertension. Vol.23
Kutzing, M.K & Firestein, B.L., 2008, Altered Uric Acid Levels and Diseases States, The Journal of Pharmacology and Experimental Theraputics, 324 (1): 1-7
Lawrence RC, Hochberg MC, Kelsey JL, McDuffie FC, Medsger TA Jr, Felts WR, et. Al. Estimates of the prevalence of selected arthritic and musculoskletal disease in the United States. J Rheumatol. 1989;16:427-41 Lehto S, Niskanen L, Ronnemma T, Laakso M. 1998. Serum Uric Acid is A
Strong Predictor of Stroke in Patients with Non-Insulin Dependent Diabetes Mellitus. Stroke, pp: 635-39.
Lilly, Gordon H. Williams dan Christopher T. Lee. 2011. Hypertension: In Patophysiology of Heart Disease, Philadelphia : Lippincott William&Wilkins
Lee WY, Park JS, Noh SY, et al. Prevalence of the metabolic syndrome among 40 698 Korean metropolitan subjects. Diabetes Res Clin Pract 2004;
65:143–149.
Liu B, Wang T, Zhao HN, Yue WW, Yu HP, Liu CX, et al. The Prevalence of Hyperuricemia in China: a Meta-Analysis. BMC Public Health.
2011;11:832
67
Liu Yuan, 2016. Prevalence and associated factors of knee osteoarthritis in a rural Chinese adult population: An Epidemiological Survey, BMC Public Health. 2016; 16: 94
Lumban, Tobing. (2008). Tekanan Darah Tinggi. Jakarta :FKUI
Mansjoer A, Triyanti K, Savitri R. 2000. Kapita Selekta Kedokteran. Jakarta:
Media Aesculapius FKUI.
Michael Doherty; New insights into the epidemiology of gout, Rheumatology, Volume 48, Issue suppl_2, 1 May 2009, Pages ii2-ii8
Mikuls TR, Farrar JT, Bilker WB, Fernandes S, Schumacher HRJr, Saag KG.
Gout epidemiology: results from the UK General Practtice Research Database, 1990-1999, Ann Rheum Dis, 2005, vol. 64 (pg. 267-72)
Niskanen LK, Laaksonen DE, Nyysonen K, Alfthan G, Lakka HM, Lakka TA, Salonen JT. 2004. Uric Acid Level as a Risk Factor for Cardiovascular and All Cause Mortality in Middle Aged Men: A Prospective Cohort Study.
Arch Itern Med, pp: 1541-46.
Putra, T.R 2006. Hiperurisemia dalam Sudoyo A.W., Setyohadi, B., Alwi l., Simadibrata K. M., Setiati S., Buku Ajar Ilmu Pemyakit Dalam, Edisi iv, 1203-1207. Pusat Penerbitan Ilmu Penyakit Dalam Universitas Indonesia, Jakarta
Rudy, Hidayat. 2009. Gout dan Hiperurisemia dalam Medicinus, Vol. 22, No. 2 edisi Juni-Agustus 2009 ISSN 1979-391x
RISKESDAS. Jakarta: Badan Penelitian dan Pengembangan Kesehatan Departemen Kesehatan, Republik Indonesia; 2007
Sherwood, Lauralee. 2001. Fisiologi Manusia : Dari Sel ke Sistem. Alih bahasa:
Brahm U. Pedit. Jakarta: EGC
Singh V, Gomez VV, Swanny SG. 2010. Approach to a Case of Hyperuricemia, Ind J Aerospace Med 54(1),2010
Sugiharto A. 2007. “Faktor-Faktor Resiko Hipertensi Grade II Pada Masyarakat” . Tesis. Semarang : Universitas Dipenogoro
Sugondo, S., 2009. Obesitas. Dalam: Sudoyo, A.W dkk., Buku Ajar Ilmu Penyakit Dalam. Jilid III. Jakarta: Interna Publishing
The Seventh Report of The Joint Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure, U.S Department of Health and Human Services, August 2004
68
Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Brunetti P. 2000. Relation between Serum Uric Acid and Risk of Cardiovascular Disease in Essential Hypertension. The PIUMA Study Hypertension, pp: 1072-78.
Winter G, Buku Pintar Kesehatan: 796 Gejala 520 Penyakit, 160 Pengobatan, alih bahasa Peter Anugerah dan Surya Satyanegara dari Judul aslinya Complete Guide to Symptoms, Ilness, & Surgery, Jakarta, Penerbitan Arcan, 1994 Wortmann. 2015. Hyperuricaemia and Gout: New Concepts in Diagnosis and
Management. Journl Postgraduate Medicine 124, 2012
Yao H, 2007, Hyperuricaemia and metabolic syndromes among males of Han ethnicity in the Xinjiang Uygur Autonomous, China, Xinjiang Medical Journal University Vol 30, No 6. Region,China,XinjiangMedicalJournal University,2007,30(6):535-538
Yogiantoro, Mohammad. 2006. Hipertensi Esensial. In: Sudoyo dkk (ed). Buku Ajar Ilmu Peyakit Dalam Jilid I Edisi IV. Jakarta: FKUI, pp: 610-14
69 LAMPIRAN 1
RIWAYAT HIDUP PENULIS
Nama : Ahmad Marwan Bin Mohd Mahali
NIM : C11114 831
Tempat Tanggal : Selangor, Malaysia. 19 Juli 1995 Lahir
Agama : Islam
Nama orang tua : Mohd Mahali Bin Kalam
Wan Mazni Bt Wan Mohamad Noor Riwayat Pendidikan :
Sekolah Rendah Islam Al farabi Klang (2002-2007) Sekolah Agama Menengah Tinggi Sultan Hishamuddin (2008-2012)
Darul Quran JAKIM (Tidak Selesai)
Universiti Selangor (2013-2014)
Universitas Hasanuddin (2014-sekarang)
70 LAMPIRAN 2
71 LAMPIRAN 3
72 LAMPIRAN 4
73 LAMPIRAN 5
74
1 LAMPIRAN 6
NO REKAM MEDIS
KATEGORI HIPERURISEMIA
USIA JENIS KELAMIN
IMT TEKANAN DARAH
KOMORBID LAMA
MENDERITA
Asam Urat
1 75239 Asimptomatik 47 L 160/90 DM Tipe 2, Stroke 4 8.8
2 75137 Asimptomatik 43 L 140/90 CAD, Dislipidemia Cushing 3 9.8
3 75096 Asimptomatik 73 P 210/100 DM Tipe 2 3 8.1
4 74974 Asimptomatik 65 L 28.04 140/90 4 6.6
5 74646 Simptomatik 66 P 150/80 Dislipidemia 4 8.3
6 74468 Asimptomatik 77 L 140/60 CHF, Dislipidemia, peptic ulcer 2 7.6
7 74416 Asimptomatik 48 P 140/70 SN Skunder, Dislipidemia 4 7.8
8 74238 Asimptomatik 64 L 180/80 CHF, CAD, AKI/CKD 4 6.6
9 74036 Asimptomatik 52 P 180/90 CHF, HDD, Dislipidemia, AKI 4 14.4
10 74013 Asimptomatik 50 P 170/80 DM tipe 2 4 8.5
11 75667 Asimptomatik 56 L 150/100 CKD 4 11.7
12 75814 Asimptomatik 68 L 19.9 140/40 DM, CKD, Dispepsia 4 7.5
13 75819 Asimptomatik 66 P 150/70 HKD 4 7.1
14 75865 Asimptomatik 51 L 220/100 3 9.9
15 76047 Asimptomatik 36 L 140/90 Dislipidemia, Kolelithiasis 2 7.5
16 76907 Asimptomatik 55 L 140/100 BSK, TB Paru 3 10.8
17 75802 Asimptomatik 64 P 150/70 3 7.5
18 12795 Asimptomatik 75 L 180/100 Dislipidemia, DM Tipe, CAD 3 10.3
19 12645 Asimptomatik 69 P 170/180 DM Tipe 2, CKD 3 7.8
20 12203 Asimptomatik 58 L 26.12 200/120 DM Tipe 2 3 7.1
21 11983 Asimptomatik 71 P 160/100 Dislipedemia, OA, HHD 3 8.7
2
22 11533 asimptomatik 65 P 160/90 DM Tipe 2, Dislipidemia 20 9.1
23 11217 asimptomatik 47 P 180/100 Dislipidemia, CAD, BSK 2 7.1
24 10760 asimptomatik 71 L 21.48 170/80 Dislipidemia 2 9.2
25 9730 asimptomatik 74 L 140/170 CAD, Dislipidemia 2 8.8
26 9234 asimptomatik 66 P 150/80 CKD/AKI, BSK, CAD, Dislipidemia 3 11.5
27 9198 asimptomatik 63 L 140/80 Dislipidemia, DM Tipe, CKD 3 7.3
28 8747 asimptomatik 73 L 150/80 BPH, OA 3 9.6
29 7784 asimptomatik 69 P 27.8 140/90 DM Tipe 2, CAD, OA 3 7.5
30 7331 asimptomatik 61 L 150/70 DM Tipe 2, CKD, CHF 3 8.7
31 6899 simptomatik 54 L 140/90 DM Tipe 2 1 7.5
32 5031 asimptomatik 65 L 28 140/90 CAD, BPH, BSK 2 9.7
33 3760 asimptomatik 63 P 140/80 DM Tipe 2, Dislipidemia, OA 2 7.4
34 2884 asimptomatik 69 L 170/90 BPH, CKD 3 9.2
35 2813 asimptomatik 60 L 34.26 140/90 Dislipidemia 2 6.5
36 2540 simptomatik 50 L 34.26 140/80 DM Tipe 2, BSK 3 7.9
37 2568 asimptomatik 64 P 29.29 170/100 OA 3 7.9
38 26992 simptomatik 82 P 140/80 DM Tipe 2, Dislipidemia, OA 3 8.6
39 27234 asimptomatik 67 P 160/90 Dislipidemia, CAD 3 7.1
40 27335 asimptomatik 49 P non
obes
140/60 Graves, DM, Dislipidemia 2 7.5
41 28746 asimptomatik 68 P 200/100 CKD, Dislipidemia, CAD 3 7.1
42 26306 simptomatik 58 L non
obes
150/90 DM Tipe 2, Dislipidemia, CKD 3 7.9
43 17528 asimptomatik 76 L 180/90 CAD, CHF, AKI 3 8
44 18282 asimptomatik 59 P non
obes
140/70 OA, CHF 3 6.5
3
45 19075 asimptomatik 49 P 23.43 170/80 DM, Dislipidemia 2 8.4
46 20895 asimptomatik 72 P 22.36 160/80 DM, Dislipidemia 2 9
47 21201 asimptomatik 77 P non
obes
180/90 DM, Dislipidemia, CAD 2 9.8
48 22546 asimptomatik 54 P 160/90 Dislipidemia, DM 2 11.1
49 23290 simptomatik 72 L non
obes
150/100 CKD/AKI, BSK, DM, 2 9.3
50 23593 simptomatik 67 L 140/90 BPH, DM, CAD, CHF 2 7.7
51 23895 asimptomatik 57 P 39.1 170/100 Dislipidemia, BSK 2 6.1
52 24075 asimptomatik 65 L 160/90 AKI, CAD, Dislipidemia 2 9
53 24078 asimptomatik 60 L 160/100 Dislipidemia, OA 2 7.6
54 24338 asimptomatik 72 L 160/100 Dislipidemia, DM Tipe 2 2 8.1
55 25386 asimptomatik 70 L 25.4 140/80 DM Tipe 2, Dislipidemia 2 9.5
56 25989 asimptomatik 52 P 140/80 DM Tipe 2, Dislipidemia 2 8.4
57 2049 asimptomatik 56 P 19.97 150/90 DM, Dislipidemi, neuropati diabetic, DKD, PJK, katarak senile
5 10.7
58 6325 asimptomatik 65 P non
obes
180/100 DM, Dislipidemi, neuropati diabetic
2014 7.4
59 10091 asimptomatik 53 L 38.4 140/90 DM, Dislipidemi, OA 2 6.1
60 10552 asimptomatik 64 P 180/80 DM, Dislipidemia 4 6.2
61 10905 simptomatik 61 L 140/80 DM, BSK, BPH, Dislipidemia 4 9
62 11759 asimptomatik 64 L 170/90 DM, Neuropati 4 9.7
63 13421 asimptomatik 53 P 180/100 DM, Dislipidemia 4 7.4
64 13700 asimptomatik 71 L 150/80 DM, CAD, Dislipidemia, CKD 3 9.2
65 14976 asimptomatik 50 L 160/100 DM, HHD 3 6.5
66 15030 asimptomatik 64 L 22.05 150/80 DM, BPH 3 8.8
4
67 16420 simptomatik 69 L non
obes
140/80 DM, Dislipidemia 2 7.6
68 16555 asimptomatik 74 L 190/100 DM, HHD 3 6.6
69 23734 asimptomatik 49 L 27.6 150/80 DM, CKD, Dislipidemia 2 8.9
70 28566 asimptomatik 51 L 160/100 DM, CKD, Dislipidemia 3 8.8
71 29668 asimptomatik 56 P 20 160/100 DM, Dislipidemi, TB, CAD, CHF, 12 8.3
72 30252 asimptomatik 57 P non
obes
150/90 DM, Dislipidemia 3 7.9
73 31780 simptomatik 78 P 21.64 150/90 DM, BSK, AKI, CAD 3 10.5
74 32578 asimptomatik 75 P 23.8 160/90 DM, Dislipidemia,CAD, TB, AKI, CHF
10 7.8
75 35227 asimptomatik 68 L 140/80 DM, BPH, Dislipidemia 2 6.6
76 35297 simptomatik 65 L Obes 150/90 DM, Dislipidemi, PJK, CAD 2 8.8
77 37719 asimptomatik 68 L 180/100 DM, Dislipidemi, BPH, CHF 1 8
78 39277 asimptomatik 57 P 24 150/90 DM, Dislipidemi, neuropati diabetic, ISK, ISPA, RA
3 7.6
79 40236 asimptomatik 63 P non
obes
150/90 DM, Dislipidemi, OA genu 2 11.5
80 40458 asimptomatik 73 L non
obes
170/80 DM, Dislipidemia, CKD 1 10.9
81 41450 asimptomatik 69 L non
obes
170/90 DM, OA, CKD, BPH 2 7.4
82 42280 asimptomatik 63 P obes 1 180/60 DM, Dislipidemia, CKD 2 8.1
83 42408 asimptomatik 60 L non
obes
150/80 DM, Dislipidemia 2 7.8
84 45109 asimptomatik 63 L 170/90 DM, Dislipidemia 2 7.1
85 50704 asimptomatik 63 P 27.4 150/90 DM, AKI 1 6.1
5
86 51788 asimptomatik 60 P 22.6 180/100 DM, dislipidemia, AKI, NHS, DKD, CHF
5 9.7
87 52450 asimptomatik 58 P Obes 190/100 DM, Dislipidemia 1 8.2
88 52637 asimptomatik 54 P 24.5 150/100 DM, CAD, CHF, AKI 20 7.7
89 52938 asimptomatik 63 P 160/100 DM, Dislipidemia 11 9
90 54076 asimptomatik 54 L non
obes
150/90 DM, Dislipidemia, CHF, AKI, CKD 3 6.8
91 55790 asimptomatik 58 P 28.9 160/80 DM, Dislipidemia, OA, DKD 7 4.6
92 56505 asimptomatik 62 L 26.21 150/90 DM, Dislipidemia, CAD, CKD, AKI 1 7.3
93 56880 asimptomatik 58 P non
obes
160/90 DM, Dislipidemia, CKD 1 7.9
94 61893 asimptomatik 51 P 29.4 160/80 DM, Dislipidemia, CKD 10 9.1
95 62988 asimptomatik 77 L 160/100 DM, DKD, Dislipidemia 1 9.7
96 64395 asimptomatik 70 L Obes 140/70 DM, Dislipidemia, DKD 10 7.4
97 66476 asimptomatik 43 P 190/100 DM, CAD, Dislipidemia 5 9.2
98 67938 asimptomatik 52 P 23.03 190/100 DM, Dislipidemia, CHF, CAD, CKD 12 6.5
99 68554 asimptomatik 47 P 24.97 160/100 DM, Dislipidemia, ISK 14 8.8
100 68669 asimptomatik 60 L 27.2 170/90 DM, CHF, CAD, CKD, BPH 10 7.6
101 69530 asimptomatik 51 P 20 140/80 DM, Dislipidemia, CAD 1 6.6
102 70460 asimptomatik 54 P Obes 140/90 DM, Dislipidemia, DKD, AKI/CKD 10 8.9
103 11759 asimptomatik 64 L 170/90 DM Tipe 2 4 8.8
104 10905 simptomatik 61 L 140/80 DM, BSK, BPH 4 8.3
105 10552 asimptomatik 64 P 180/80 DM, Dislipidemia 4 7.9
106 10091 asimptomatik 53 L 31.84 140/90 DM, Dislipidemia, OA 2 10.5
107 6325 asimptomatik 65 P non
obes
180/100 DM, Dislipidemia 3 7.8
6
108 47246 simptomatik 58 L 30.12 140/80 BSK, CKD 1 6.6
109 68998 asimptomatik 51 P 170/80 Hipertiroid 1 7.2
110 68797 asimptomatik 75 P 160/100 DM, Neuropati, CAD, Dislipidemia 1 8.3
111 68671 asimptomatik 64 P 160/100 Hipertiroid 1 6.7
112 68614 asimptomatik 48 L 120/80 1 7
113 68382 simptomatik 57 L 20.31 170/90 DM, Dislipidemia 1 8
114 67312 asimptomatik 44 L 160/100 CKD 1 9.5
115 67086 asimptomatik 63 P 130/70 CHF 1 7.3
116 67072 simptomatik 60 P 180/100 HHD, Dislipidemia 1 7.8
117 65485 asimptomatik 63 L 170/100 CHF, Dislipidemia 1 7
118 60927 asimptomatik 71 P 180/100 CHF, HHD 1 7
119 60777 asimptomatik 57 L 140/100 CHD, HHD, Dislipidemia <1 7.5
120 60395 asimptomatik 63 P non
obes
180/100 OA, DM, Dislipidemia 1 7.6
121 57741 asimptomatik 62 P 170/100 CKD, Dislipidemia, Nefropati 1 8.7
122 60944 asimptomatik 63 L 140/80 DM, Dislipidemia, Neuropati 1 7.5
123 60977 asimptomatik 55 P non
obes
140/90 DM, Dslipidemia, OA 1 6
124 61091 asimptomatik 72 L 160/80 DM, HHD, Dislipidemia 1 6.1
125 61106 asimptomatik 33 L 160/90 CKD 1 8.7
126 61482 asimptomatik 63 P Obes 190/90 CHF, Dislipidemia 1 9.8
127 61904 asimptomatik 58 P 170/90 1 9.7
128 62303 asimptomatik 67 P 140/90 DM, Hipertiroid, Dislipidemia 1 7.4
129 64544 asimptomatik 66 L 28.58 160/100 CAD, Dislipidemia 1 9.2
130 65042 asimptomatik 60 L 140/100 Dislipidemia 1 9
131 66491 asimptomatik 69 L 170/90 Dislipidemia, HKD 1 9
7
132 69149 asimptomatik 20 L 140/100 1 8.6
133 52133 asimptomatik 58 L 150/100 CHF, CAD, Dislipidemia 1 7.3
134 51144 asimptomatik 78 P 15.22 160/80 HKD, BSK, CKD 15 6.8
135 49732 asimptomatik 70 P 180/80 DM, AKI, Dislipidemia 2 9.7
136 47781 asimptomatik 80 P 180/100 Dislipidemia, OA 1 7.4
137 47325 simptomatik 74 L 140/80 Dislipidemia 2 9.2
138 46321 asimptomatik 62 L 34.06 140/80 DM, Dislipidemia, Neuropati 2 6.5
139 46099 asimptomatik 71 L 140/90 CKD, Dislipidemia 2 9.1
140 45874 asimptomatik 60 L 26.34 180/100 BPH, Dislipidemia, HHD 2 7.8
141 43793 asimptomatik 59 L non
obes
160/100 DM, Dislipidemia 1 7
142 43641 asimptomatik 68 L 33.69 160/100 OA 2 8.5
143 41763 asimptomatik 61 L 160/90 CAD, Dislipidemia 2 7.7
144 41270 asimptomatik 77 L 200/90 Dislipidemia 2 7.6
145 41251 asimptomatik 69 P 25.3 140/80 CHF, HHD, Dislipidemia 2 9
146 40955 asimptomatik 71 P 160/80 Dislipidemia 2 8.6
147 40116 asimptomatik 36 P 140/80 1 7.3
148 64263 simptomatik 45 L 25.57 160/80 1 7
149 63264 asimptomatik 51 L non
obes
160/90 BSK 1 9.9
150 61692 asimptomatik 72 P 29.29 160/90 CHF, HHD 1 8.3
151 59107 asimptomatik 62 P 18.58 170/100 DM, CKD 1 7
152 54376 asimptomatik 48 P 19.5 140/60 DM, CKD 2 7.2
153 73014 asimptomatik 55 L 24.09 150/100 Bulanan 9.5
154 73675 asimptomatik 73 L 160/100 Bulanan 7
155 73584 asimptomatik 55 L 150/90 Dislipidemia Bulanan 8.1
8
156 73467 asimptomatik 56 P non
obes
160/100 DM, Dislipidemia, BSK Bulanan 6.5
157 73063 asimptomatik 56 L 180/100 Bulanan 9.5
158 71582 asimptomatik 67 L 140/80 Dislipidemia Bulanan 8
159 72045 asimptomatik 55 P 140/80 CHF, DM, DKD 1 11.5
160 72853 asimptomatik 63 L 150/60 CAD Bulanan 8
161 34521 simptomatik 55 P 170/90 Dislipidemia 2 7.1
162 35518 asimptomatik 75 L 140/70 BPH, HHD Bulanan 10.1
163 35975 asimptomatik 78 P 160/80 DM, Dislipidemia, OA 1 6.5
164 35990 simptomatik 77 L non
obes
160/80 DM, CAD, Dislipidemia 1 7.7
165 36899 asimptomatik 65 L 170/100 CAD, DM, HHD 2 8
166 37089 asimptomatik 51 L 140/90 5 7.3
167 37318 asimptomatik 64 L 170/90 HHD 2 7.9
168 37625 asimptomatik 53 L 140/90 CAD, Dislipidemia, BPH 2 9
169 33914 asimptomatik 70 P 160/100 2 7.7
170 34886 asimptomatik 70 P 140/70 DM, Dislipidemia 2 7
171 35171 asimptomatik 67 P 150/80 OA, CAD 2 7.2
172 35210 asimptomatik 22 L Obes 160/100 SN, Dislipidemia 2 8.3
173 32103 asimptomatik 46 P 140/100 DM, Dislipidemia 3 6.1
174 32280 asimptomatik 62 L 160/90 DM, CAD, HHD, BPH 10 7.1
175 32452 asimptomatik 50 P non
obes
160/80 Graves, DM 3 7.3
176 32006 asimptomatik 64 L 150/70 CAD, DM, Dislipidemia 3 6.9
177 56456 simptomatik 63 P non
obes
130/70 DM, Dislipidemia, OA Bulanan 7.1
9
178 56447 asimptomatik 58 P 160/80 DM, Dislipidemia, BSK Bulanan 5.6
179 56283 asimptomatik 53 P 140/80 Dislipidemia Bulanan 7
180 55025 simptomatik 70 L 170/120 Dislipidemia, CKD 1 8.4
181 54968 asimptomatik 43 L Obes 140/100 DM, Dislipidemia 1 7.1
182 54156 simptomatik 63 P 140/70 DM, Dislipidemia Bulanan 6.6
183 52656 asimptomatik 73 P 160/90 Dislipidemia, OA 1 8.1
184 51064 asimptomatik 63 P 180/50 Graves, Dislipidemia, OA 2 6.3
185 35253 asimptomatik 59 P 21.4 160/80 DM, CHF 10 7.1
186 18176 asimptomatik 63 P 24 160/70 DM, Dislipidemila, DKD 1 8.6
187 19994 asimptomatik 71 P non
obes
160/80 DM, Dislipidemia 7 8.5
188 14235 asimptomatik 45 L 140/80 1 7
189 4003 asimptomatik 64 P 33 160/90 OA, Dislipidemia 2 6.1
190 12971 asimptomatik 59 P non
obes
160/80 DM, Dislipidemia 1 6.5
191 14467 simptomatik 58 L non
obes
190/100 Dislipidemia 3 10.6
192 15199 asimptomatik 63 P 160/100 Dislipidemia 2 8.9
193 15797 asimptomatik 72 L 31.25 160/80 CHF, Dislipidemia, CKD, BPH Bulanan 8
194 37972 asimptomatik 74 L 28.96 140/80 Dislipidemia 2 8.4
195 37767 asimptomatik 70 P 180/90 Dislipidemia, OA, BSK 2 8.6
196 26786 asimptomatik 54 P 140/100 CAD, HHD, Dislipidemia 3 9.5
197 29729 asimptomatik 60 L 19.5 140/90 DM Bulanan 7
198 30580 asimptomatik 66 P 160/90 CAD, DM, Dislipidemia 2 7.6
199 39021 asimptomatik 62 L 24.22 160/100 CAD, OA, Dislipidemia 2 8.3
200 39478 asimptomatik 47 P non 140/80 CAD, Dislipidemia Bulanan 5.9